(Q28292264)

Chemotherapy targeted to cancers through tumoral hormone receptors

21 January 2018

1 reference

Targeted therapy: wave of the future.

21 January 2018

1 reference

21 January 2018

Targeted cancer therapy

1 reference

New science-based endpoints to accelerate oncology drug development

21 January 2018

1 reference

Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics

21 January 2018

1 reference

Tyrosine kinase receptors as attractive targets of cancer therapy

21 January 2018

1 reference

New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors

21 January 2018

1 reference

Epidermal growth factor receptors: critical mediators of multiple receptor pathways

21 January 2018

1 reference

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

21 January 2018

1 reference

The EGF receptor family as targets for cancer therapy

21 January 2018

1 reference

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

21 January 2018

1 reference

Targeting the epidermal growth factor receptor

21 January 2018

1 reference

The biology of epidermal growth factor receptor in lung cancer

21 January 2018

1 reference

The epidermal growth factor receptor as a target for gastrointestinal cancer therapy

21 January 2018

1 reference

Role of HER2/neu in tumor progression and therapy

21 January 2018

1 reference

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.

21 January 2018

1 reference

The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells

21 January 2018

1 reference

Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.

21 January 2018

1 reference

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

21 January 2018

1 reference

Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance

21 January 2018

1 reference

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

21 January 2018

1 reference

Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.

21 January 2018

1 reference

Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.

21 January 2018

1 reference

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

21 January 2018

1 reference

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

Practical management of patients with non-small-cell lung cancer treated with gefitinib

21 January 2018

1 reference

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.

21 January 2018

1 reference

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

21 January 2018

1 reference

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

Cetuximab (Erbitux)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours

21 January 2018

1 reference

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

Receptor-targeted cancer therapy

21 January 2018

1 reference

Drug metabolism and variability among patients in drug response

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1G387

1 reference

Consolidated OpenCitations Corpus – April 2017

2614821

2614821

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference